Then in 2006, CAT was bought by AstraZeneca for £700 million, dashing hopes that the UK could produce a world-class biotech to rival the success of US companies Amgen and Genentech. This pattern ...

Combine this with a large increase in funding, and you could start to see the rewards of leading a UK biotech company to success start to become enticing – the $354 million that David Hung ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

announced an investment and strategic partnership with UK-based Juvenescence , a longevity-focused biotechnology company. M42 was launched by G42 Healthcare , the healthcare arm of the UAE's ...

PIC's gene-edited pigs are highly resistant to one of the most harmful viruses affecting pig populations worldwide today.

a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31 ...

Stablepharma Ltd is a high-growth biotechnology company based in the UK and Spain, with the mission to reduce reliance on the pharmaceutical cold-chain. Stablepharma's vision is to save lives ...

Regardless of the macroeconomic environment, we remain focused on applying our well-established, long-term, bottom-up EQV ...

Co-development Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-development deals. Fully revised and updated, the report ...